Form 4 for MLTX MoonLake Immunotherapeutics
Accepted 2025-12-10 00:00:00 ET · period of report 2025-12-08 · accession 0001213900-25-120106 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-12-10 | 2025-12-08+ | MLTX | Santos da Silva Jorge | CEO, Dir | S - Sale | $14.87 | -200.0K | 2.95M | -6% | -$2.97M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A ordinary shares, par value $0.0001 per share | 2025-12-09 | S | D | 70,000 | $14.49 | 2,878,577 | D | — | — | (F1) Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales. |
| 2 | Common | Class A ordinary shares, par value $0.0001 per share | 2025-12-08 | S | D | 130,000 | $15.08 | 2,948,577 | D | — | — | (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.045789 to $15.098641. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F1) Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales. |